Last reviewed · How we verify
LCAR- F33S cells intravenous infusion — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LCAR- F33S cells intravenous infusion (LCAR- F33S cells intravenous infusion) — Nanjing Legend Biotech Co..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LCAR- F33S cells intravenous infusion TARGET | LCAR- F33S cells intravenous infusion | Nanjing Legend Biotech Co. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LCAR- F33S cells intravenous infusion CI watch — RSS
- LCAR- F33S cells intravenous infusion CI watch — Atom
- LCAR- F33S cells intravenous infusion CI watch — JSON
- LCAR- F33S cells intravenous infusion alone — RSS
Cite this brief
Drug Landscape (2026). LCAR- F33S cells intravenous infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/lcar-f33s-cells-intravenous-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab